Pitella Felipe Arriva, Alexandre-Santos Leonardo, de Lacerda Kleython José Coriolano Cavalcanti, Trevisan Ana Carolina, Kato Mery, Padovan-Neto Fernando Eduardo, Tumas Vitor, Wichert-Ana Lauro
Nuclear Medicine and PET/CT Section, Department of Medical Imaging, Hematology and Clinical Oncology, Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil.
Department of Psychology, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto da Universidade de São Paulo (FFCLRP-USP), Ribeirão Preto, SP, Brazil.
Radiol Bras. 2024 Jul 24;57:e20230082. doi: 10.1590/0100-3984.2023.0082. eCollection 2024 Jan-Dec.
To compare the dopamine transporter (DAT) density with other risk factors for L-DOPA-induced dyskinesia (LID) in patients with Parkinson's disease (PD), with and without LID.
We evaluated 67 subjects: 44 patients with idiopathic PD of varying degrees of severity (PD group), and 23 healthy age-matched volunteers (control group). Among the 44 patients in the PD group, 29 were male and the following means were recorded at baseline: age, 59 ± 7 years; disease duration, 10 ± 6 years; Hoehn and Yahr (H&Y) stage, 2.16 ± 0.65; and Unified Parkinson's Disease Rating Scale part III (UPDRS III) score, 29.74 ± 17.79. All subjects underwent Tc-TRODAT-1 SPECT. We also calculated specific uptake ratios or binding potentials in the striatum.
The DAT density in the ipsilateral and contralateral striata was lower in the PD group. The variables disease duration, L-DOPA dosage, doses per day, L-DOPA effect duration time, H&Y stage, and UPDRS III score explained the occurrence of LID. The DAT density in the ipsilateral striatum, contralateral striatum, and caudate nucleus was lower in the patients with LID than in those without.
Our findings suggest that presynaptic dopaminergic denervation is associated with LID in individuals with PD.
比较帕金森病（PD）患者伴或不伴左旋多巴诱导的异动症（LID）时多巴胺转运体（DAT）密度与LID其他危险因素。
我们评估了67名受试者：44例不同严重程度的特发性PD患者（PD组），以及23名年龄匹配的健康志愿者（对照组）。PD组的44例患者中，男性29例，基线时记录以下均值：年龄59±7岁；病程10±6年；Hoehn和Yahr（H&Y）分期2.16±0.65；统一帕金森病评定量表第三部分（UPDRS III）评分29.74±17.79。所有受试者均接受99m锝-替曲膦（Tc-TRODAT-1）单光子发射计算机断层扫描（SPECT）。我们还计算了纹状体中的特异性摄取率或结合电位。
PD组同侧和对侧纹状体中的DAT密度较低。病程、左旋多巴剂量、每日剂量、左旋多巴作用持续时间、H&Y分期和UPDRS III评分等变量可解释LID的发生。LID患者同侧纹状体、对侧纹状体和尾状核中的DAT密度低于无LID患者。
我们的研究结果表明，突触前多巴胺能去神经支配与PD患者的LID相关。
